Zacopride

Zacopride
Clinical data
ATC code
  • none
Identifiers
IUPAC name
  • 4-amino-5-chloro-2-methoxy-N-(quinuclidin-3-yl)benzamide
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC15H20ClN3O2
Molar mass309.79 g·mol−1
3D model (JSmol)
SMILES
  • COC1=CC(=C(C=C1C(=O)NC2CN3CCC2CC3)Cl)N
InChI
  • InChI=1S/C15H20ClN3O2/c1-21-14-7-12(17)11(16)6-10(14)15(20)18-13-8-19-4-2-9(13)3-5-19/h6-7,9,13H,2-5,8,17H2,1H3,(H,18,20) ☒N
  • Key:FEROPKNOYKURCJ-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Zacopride is a potent antagonist at the 5-HT3 receptor[1] and an agonist at the 5-HT4 receptor.[2] It has anxiolytic[3] and nootropic effects in animal models,[4] with the (R)-(+)-enantiomer being the more active form.[5] It also has antiemetic[6] and pro-respiratory effects, both reducing sleep apnea[7] and reversing opioid-induced respiratory depression in animal studies.[8] Early animal trials have also revealed that administration of zacopride can reduce preference for and consumption of ethanol.[9]

Zacopride was found to significantly increase aldosterone levels in human subjects for 180 minutes at a dose of 400 micrograms. It is thought to do this by stimulating the 5-HT4 receptors on the adrenal glands. Zacopride also stimulated aldosterone secretion when applied to human adrenal glands in vitro. No significant changes were observed in renin, ACTH, or cortisol levels.[2]

Zacopride has been tested in clinical trials for the treatment of schizophrenia, but was found unsuccessful.[10]

References

  1. ↑ Smith WW, Sancilio LF, Owera-Atepo JB, Naylor RJ, Lambert L (April 1988). "Zacopride, a potent 5-HT3 antagonist". The Journal of Pharmacy and Pharmacology. 40 (4): 301–2. doi:10.1111/j.2042-7158.1988.tb05253.x. PMID 2900319. S2CID 32862252.
  2. 1 2 Lefebvre H, Contesse V, Delarue C, Soubrane C, Legrand A, Kuhn JM, et al. (December 1993). "Effect of the serotonin-4 receptor agonist zacopride on aldosterone secretion from the human adrenal cortex: in vivo and in vitro studies". The Journal of Clinical Endocrinology and Metabolism. 77 (6): 1662–6. doi:10.1210/jc.77.6.1662. PMID 8263156.
  3. ↑ Costall B, Domeney AM, Gerrard PA, Kelly ME, Naylor RJ (April 1988). "Zacopride: anxiolytic profile in rodent and primate models of anxiety". The Journal of Pharmacy and Pharmacology. 40 (4): 302–5. doi:10.1111/j.2042-7158.1988.tb05254.x. PMID 2900320. S2CID 1083706.
  4. ↑ Fontana DJ, Daniels SE, Eglen RM, Wong EH (March 1996). "Stereoselective effects of (R)- and (S)-zacopride on cognitive performance in a spatial navigation task in rats". Neuropharmacology. 35 (3): 321–7. doi:10.1016/0028-3908(96)00191-8. PMID 8783207. S2CID 12818436.
  5. ↑ Young R, Johnson DN (August 1991). "Anxiolytic-like activity of R(+)- and S(-)-zacopride in mice". European Journal of Pharmacology. 201 (2–3): 151–5. doi:10.1016/0014-2999(91)90338-Q. PMID 1686755.
  6. ↑ Yamakuni H, Nakayama H, Matsui S, Imazumi K, Matsuo M, Mutoh S (May 2006). "Inhibitory effect of zacopride on Cisplatin-induced delayed emesis in ferrets". Journal of Pharmacological Sciences. 101 (1): 99–102. doi:10.1254/jphs.SCJ05007X. PMID 16651699.
  7. ↑ Carley DW, Depoortere H, Radulovacki M (2001). "R-zacopride, a 5-HT3 antagonist/5-HT4 agonist, reduces sleep apneas in rats". Pharmacology, Biochemistry, and Behavior. 69 (1–2): 283–9. doi:10.1016/S0091-3057(01)00535-4. PMID 11420096. S2CID 11848748.
  8. ↑ Meyer LC, Fuller A, Mitchell D (February 2006). "Zacopride and 8-OH-DPAT reverse opioid-induced respiratory depression and hypoxia but not catatonic immobilization in goats". American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 290 (2): R405-13. doi:10.1152/ajpregu.00440.2005. PMID 16166206. S2CID 224414.
  9. ↑ Knapp DJ, Pohorecky LA (April 1992). "Zacopride, a 5-HT3 receptor antagonist, reduces voluntary ethanol consumption in rats". Pharmacology, Biochemistry, and Behavior. 41 (4): 847–50. doi:10.1016/0091-3057(92)90237-A. PMID 1594653. S2CID 45436887.
  10. ↑ Newcomer JW, Faustman WO, Zipursky RB, Csernansky JG (September 1992). "Zacopride in schizophrenia: a single-blind serotonin type 3 antagonist trial". Archives of General Psychiatry. 49 (9): 751–2. doi:10.1001/archpsyc.1992.01820090079013. PMID 1514881.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.